RFG
ALLO icon

REAP Financial Group’s Allogene Therapeutics ALLO Stock Holding History

REAP Financial Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$226 – 519
2025
Q2 		$226 Hold
200
– – ﹤0.01% 487
2025
Q1 		$292 Hold
200
– – ﹤0.01% 519
2024
Q4 		$426 Hold
200
– – ﹤0.01% 549
2024
Q3 		$560 Hold
200
– – ﹤0.01% 560
2024
Q2 		$466 Hold
200
– – ﹤0.01% 515
2024
Q1 		$894 Buy
+200
New +$835 ﹤0.01% 539

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

REAP Financial Group's ALLO Position: Q3 2025 in Review

REAP Financial Group sold out of Allogene Therapeutics (ALLO) in Q3 2025, closing a stake of 200 shares — an estimated $226 sold.

REAP Financial Group first reported a position in ALLO in Q1 2024 and held it in 6 quarters. The position peaked at $894 in Q1 2024. 170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • REAP Financial Group reported no remaining Allogene Therapeutics position as of Q3 2025 after selling out during the quarter.
  • REAP Financial Group sold 200 Allogene Therapeutics shares in Q3 2025, an estimated $226.
  • REAP Financial Group first reported a position in Allogene Therapeutics in Q1 2024 and held it in 6 quarters.
  • REAP Financial Group's Allogene Therapeutics position peaked at $894 in Q1 2024.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on REAP Financial Group's 13F filing for Q3 2025, filed 6 Nov 2025.